https://mindmedicinelaw.com/briefing/mdma-assisted-therapy-nears-potential-fda-approval-in-the-us-20261023-53220The Psychedelic Journalen2026-10-23T22:04:21.564040+00:00MDMA-Assisted Therapy Nears Potential FDA Approval in the USmdma-assisted therapy, fda approval, psychedelic regulation, clinical trials, dea rescheduling, ptsd treatment, risk mitigation, health policy, lykos therapeutics, psychedelic medicinehttps://mindmedicinelaw.com/briefing/oregon-state-university-trials-psychedelic-therapy-for-end-of-life-distress-20261023-53046The Psychedelic Journalen2026-10-23T15:06:10.804697+00:00Oregon State University Trials Psychedelic Therapy for End-of-Life Distresspsychedelic-assisted therapy, oregon state university, cancer palliative care, clinical trial, end-of-life distress, psilocybin, oncology, fda regulation, insurance coverage, mental healthhttps://mindmedicinelaw.com/briefing/microglial-mitochondrial-dysfunction-and-depression-implications-for-psychedelic-20261022-52981The Psychedelic Journalen2026-10-23T15:07:27.917345+00:00Microglial Mitochondrial Dysfunction and Depression: Implications for Psychedelic Researchmicroglia, mitochondrial dysfunction, depression pathogenesis, neuroinflammation, psychedelic research, clinical trials, neuroimmune modulation, biomarkers, major depressive disorderhttps://mindmedicinelaw.com/briefing/subanesthetic-ketamine-for-opioid-refractory-cancer-pain-clinical-evidence-and-p-20261022-52980The Psychedelic Journalen2026-10-23T15:06:55.637847+00:00Subanesthetic Ketamine for Opioid-Refractory Cancer Pain: Clinical Evidence and Policy Outlooksubanesthetic ketamine, opioid-refractory cancer pain, analgesia, opioid-sparing, clinical trials, nmda receptor antagonists, adverse effects, palliative care, policy implications, pain managementhttps://mindmedicinelaw.com/briefing/lsd-extends-lifespan-in-c-elegans-mechanisms-and-implications-20261022-52930The Psychedelic Journalen2026-10-23T15:06:36.903152+00:00LSD Extends Lifespan in C. elegans: Mechanisms and Implicationslsd, c. elegans, serotonergic pathways, aging research, lifespan extension, nutrient-sensing, preclinical study, psychedelic science, gpcr signalinghttps://mindmedicinelaw.com/briefing/cost-effectiveness-of-ketamine-vs-ect-in-us-depression-care-20261022-52806The Psychedelic Journalen2026-10-22T22:05:06.409472+00:00Cost-Effectiveness of Ketamine vs. ECT in US Depression Careketamine, electroconvulsive therapy, treatment-resistant depression, cost-effectiveness, quality-adjusted life-years, clinical guidelines, health policy, insurance reimbursement, psychiatric treatments, depression carehttps://mindmedicinelaw.com/briefing/cbp-delays-de-minimis-exemption-suspension-implications-for-psychedelic-imports-20261022-52553The Psychedelic Journalen2026-10-22T15:05:42.120726+00:00CBP Delays De Minimis Exemption Suspension: Implications for Psychedelic Importscbp de minimis exemption, psychedelic research imports, mail shipment regulation, customs compliance, research chemicals, us customs and border protection, policy change, supply chain risk, federal register, drug import controlshttps://mindmedicinelaw.com/briefing/pediatric-perioperative-esketamine-dose-dependent-effects-and-unresolved-safety--20261021-52985The Psychedelic Journalen2026-10-23T15:07:44.751681+00:00Pediatric Perioperative Esketamine: Dose-Dependent Effects and Unresolved Safety Boundariesesketamine, pediatric anesthesia, emergence delirium, dose-dependent effects, perioperative care, clinical trials, safety boundaries, pharmacokinetics, endpoint-specific outcomeshttps://mindmedicinelaw.com/briefing/esketamine-ect-combination-in-adolescent-depression-interim-trial-insights-20261021-52983The Psychedelic Journalen2026-10-23T15:05:50.517684+00:00Esketamine-ECT Combination in Adolescent Depression: Interim Trial Insightsesketamine, electroconvulsive therapy, adolescent depression, suicidal ideation, randomized controlled trial, cognitive safety, psychiatric protocols, regulatory policy, major depressive disorderhttps://mindmedicinelaw.com/briefing/low-dose-ketamine-for-depression-clinical-evidence-and-policy-in-2026-20261021-52631The Psychedelic Journalen2026-10-22T15:05:14.694482+00:00Low-Dose Ketamine for Depression: Clinical Evidence and Policy in 2026ketamine, treatment-resistant depression, bipolar depression, meta-analysis, clinical guidelines, long-term safety, FDA, psychiatry, rapid-acting antidepressants, policy implicationshttps://mindmedicinelaw.com/briefing/expectation-bias-in-psychedelic-trials-implications-for-research-validity-20261021-52617The Psychedelic Journalen2026-10-22T15:04:58.859041+00:00Expectation Bias in Psychedelic Trials: Implications for Research Validitypsychedelic clinical trials, expectation bias, participant selection, trial generalizability, regulatory implications, chronic pain research, personality traits, clinical trial design, selection bias, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-wellbeing-gains-in-social-anxiety-trials-20261020-52779The Psychedelic Journalen2026-10-22T22:05:18.856215+00:00MDMA-Assisted Therapy: Wellbeing Gains in Social Anxiety Trialsmdma-assisted therapy, social anxiety disorder, self-transcendent emotions, psychological flourishing, clinical trial outcomes, wellbeing measures, psychedelic research, regulatory implications, mechanisms of actionhttps://mindmedicinelaw.com/briefing/omics-informed-tms-mechanisms-in-trd-implications-for-psychedelic-research-20261020-52618The Psychedelic Journalen2026-10-22T15:05:58.125417+00:00Omics-Informed TMS Mechanisms in TRD: Implications for Psychedelic Researchtranscranial magnetic stimulation, treatment-resistant depression, omics, biomarkers, neuroplasticity, psychedelic research, clinical trial design, mechanisms of action, regulatory policyhttps://mindmedicinelaw.com/briefing/psychedelic-like-vr-for-ocd-feasibility-trial-in-germany-and-italy-20261019-52970The Psychedelic Journalen2026-10-23T15:07:12.342590+00:00Psychedelic-Like VR for OCD: Feasibility Trial in Germany and Italyvirtual reality, psychedelic simulation, obsessive-compulsive disorder, clinical trial, digital therapeutics, psychological flexibility, feasibility study, mental health policyhttps://mindmedicinelaw.com/briefing/social-responsibility-in-psychedelic-research-integrating-ethnic-minorities-20261019-52621The Psychedelic Journalen2026-10-22T15:06:11.926716+00:00Social Responsibility in Psychedelic Research: Integrating Ethnic Minoritiespsychedelic research, ethnic minority integration, indigenous communities, afro-descendant inclusion, social responsibility, decolonizing methodologies, health policy, extractive industries, intercultural justice, benefit sharinghttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-alters-dna-methylation-in-mdd-patients-20261015-52691The Psychedelic Journalen2026-10-22T15:05:27.212174+00:00Ketamine-Assisted Psychotherapy Alters DNA Methylation in MDD Patientsketamine-assisted psychotherapy, dna methylation, major depressive disorder, epigenetics, psychedelic research, biomarker development, clinical trial design, regulatory policy, psychiatric intervention, longitudinal study